Handelsbanken Fonder AB bought a new stake in shares of 23andMe Holding Co. (NASDAQ:ME – Get Rating) during the 4th quarter, HoldingsChannel.com reports. The firm bought 101,600 shares of the company’s stock, valued at approximately $219,000.
Other institutional investors have also made changes to their positions in the company. Advisor Group Holdings Inc. raised its holdings in shares of 23andMe by 21.8% in the first quarter. Advisor Group Holdings Inc. now owns 54,620 shares of the company’s stock valued at $210,000 after buying an additional 9,765 shares during the last quarter. Swiss National Bank lifted its stake in 23andMe by 64.8% in the first quarter. Swiss National Bank now owns 219,400 shares of the company’s stock valued at $840,000 after buying an additional 86,300 shares in the last quarter. ProShare Advisors LLC lifted its position in 23andMe by 26.1% in the 1st quarter. ProShare Advisors LLC now owns 21,854 shares of the company’s stock valued at $84,000 after acquiring an additional 4,525 shares in the last quarter. JPMorgan Chase & Co. grew its position in 23andMe by 83.0% in the first quarter. JPMorgan Chase & Co. now owns 86,111 shares of the company’s stock valued at $330,000 after purchasing an additional 39,066 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in 23andMe by 168.5% during the first quarter. Bank of New York Mellon Corp now owns 91,142 shares of the company’s stock worth $349,000 after acquiring an additional 57,198 shares in the last quarter. 29.49% of the stock is currently owned by institutional investors and hedge funds.
23andMe Price Performance
NASDAQ:ME opened at $2.16 on Tuesday. The firm has a fifty day simple moving average of $2.20 and a 200 day simple moving average of $2.52. 23andMe Holding Co. has a 1-year low of $1.74 and a 1-year high of $6.31.
23andMe Holding Co operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit.
- Get a free copy of the StockNews.com research report on 23andMe (ME)
- Is the Electric Vehicle Movement Losing Steam?
- 3 High-Yield Banks Insiders Are Buying
- Will ChatGPT Be the Final Nail in the Coffin for Chegg?
- Is the Market Reacting Too Negatively to Pinterest Earnings?
- More Analysts Should See Energizer Holdings As A Buy: Here Is Why
Want to see what other hedge funds are holding ME? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 23andMe Holding Co. (NASDAQ:ME – Get Rating).
Receive News & Ratings for 23andMe Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 23andMe and related companies with MarketBeat.com's FREE daily email newsletter.